You are here
Advisory Panel Split on Drug for Familial Amyloid Polyneuropathy
The U.S. Food and Drug Administration panel voted 13 to 4 that the drug did not show that it met the main goal in a study in treating the fatal condition. However, the panel also voted 13 to 4 that the drug treated a surrogate endpoint, which may correlate with treating the underlying disease.
The panel's recommendation will be considered by the U.S. Food and Drug Administration when it takes a decision on tafamidis, a relatively minor product for the world's largest drugmaker.
Read the full article on Reuters.